TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients

PHASE3RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Antibody-mediated Rejection
Interventions
DRUG

Tocilizumab

Tocilizumab is a recombinant humanized monoclonal antibody directed against the human interleukin-6 (IL-6) receptor

Trial Locations (8)

Unknown

NOT_YET_RECRUITING

Complejo Hospitalario Universitario A Coruña, A Coruña

ACTIVE_NOT_RECRUITING

Hospital del Mar, Barcelona

NOT_YET_RECRUITING

Marqués de Valdecilla Research Institute, Santander

NOT_YET_RECRUITING

Hospital Universitario Dr. Peset, Valencia

RECRUITING

Transplant Center, Sahlgrenska University Hospital, Gothenburg

214 28

RECRUITING

Skåne University Hospital, Malmo

SE-141 86

RECRUITING

Karolinksa University Hospital, Stockholm

751 85

RECRUITING

Uppsala University Hospital, Uppsala

All Listed Sponsors
collaborator

Karolinska University Hospital

OTHER

collaborator

Uppsala University Hospital

OTHER

collaborator

Skane University Hospital

OTHER

collaborator

The Swedish Research Council

OTHER_GOV

collaborator

Hospital del Mar

OTHER

collaborator

Hospital Universitario Doctor Peset

OTHER

collaborator

Complexo Hospitalario Universitario de A Coruña

OTHER

collaborator

Hospital Universitario Marqués de Valdecilla

OTHER

lead

Vastra Gotaland Region

OTHER_GOV

NCT04561986 - TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients | Biotech Hunter | Biotech Hunter